OBJECTIVES: Increased bone marrow iron levels in patients with haematological malignancies is an independent risk factor for developing invasive pulmonary aspergillosis (IPA), suggesting an important role for iron uptake in the pathogenesis of IPA. We sought to determine the potential for combination therapy with the iron chelator deferasirox + liposomal amphotericin B (LAmB) to improve the outcome of murine IPA compared with LAmB monotherapy. METHODS: In vitro MIC and minimum fungicidal concentration (MFC) values of the iron chelator, deferasirox, for Aspergillus fumigatus were determined by microdilution assay. In addition, we studied the efficacy of deferasirox alone or combined with LAmB in treating immunocompromised mice infected with A. fumigatus via inhalation. RESULTS: Deferasirox was cidal in vitro against A. fumigatus, with an MIC and MFC of 25 and 50 mg/L, respectively. Deferasirox monotherapy modestly prolonged survival of mice with IPA. Combination deferasirox + LAmB therapy synergistically improved survival and reduced lung fungal burden compared with either monotherapy alone. CONCLUSIONS: Iron chelation therapy with deferasirox alone or in combination with LAmB is effective in treating experimental IPA. Further study of deferasirox is warranted as adjunctive therapy for IPA infections.
OBJECTIVES: Increased bone marrow iron levels in patients with haematological malignancies is an independent risk factor for developing invasive pulmonary aspergillosis (IPA), suggesting an important role for iron uptake in the pathogenesis of IPA. We sought to determine the potential for combination therapy with the iron chelator deferasirox + liposomal amphotericin B (LAmB) to improve the outcome of murine IPA compared with LAmB monotherapy. METHODS: In vitro MIC and minimum fungicidal concentration (MFC) values of the iron chelator, deferasirox, for Aspergillus fumigatus were determined by microdilution assay. In addition, we studied the efficacy of deferasirox alone or combined with LAmB in treating immunocompromised mice infected with A. fumigatus via inhalation. RESULTS:Deferasirox was cidal in vitro against A. fumigatus, with an MIC and MFC of 25 and 50 mg/L, respectively. Deferasirox monotherapy modestly prolonged survival of mice with IPA. Combination deferasirox + LAmB therapy synergistically improved survival and reduced lung fungal burden compared with either monotherapy alone. CONCLUSIONS:Iron chelation therapy with deferasirox alone or in combination with LAmB is effective in treating experimental IPA. Further study of deferasirox is warranted as adjunctive therapy for IPA infections.
Authors: Dimitrios P Kontoyiannis; Georgios Chamilos; Russell E Lewis; Sergio Giralt; Jorge Cortes; Issam I Raad; John T Manning; Xin Han Journal: Cancer Date: 2007-09-15 Impact factor: 6.860
Authors: Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw Journal: N Engl J Med Date: 2002-08-08 Impact factor: 91.245
Authors: Donald C Sheppard; Gunter Rieg; Lisa Y Chiang; Scott G Filler; John E Edwards; Ashraf S Ibrahim Journal: Antimicrob Agents Chemother Date: 2004-05 Impact factor: 5.191
Authors: A Altes; A F Remacha; P Sarda; F J Sancho; A Sureda; R Martino; J Briones; S Brunet; C Canals; J Sierra Journal: Bone Marrow Transplant Date: 2004-09 Impact factor: 5.483
Authors: Ashraf S Ibrahim; Teclegiorgis Gebermariam; Yue Fu; Lin Lin; Mohamed I Husseiny; Samuel W French; Julie Schwartz; Christopher D Skory; John E Edwards; Brad J Spellberg Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808
Authors: Livio Pagano; Oliver A Cornely; Alessandro Busca; Morena Caira; Simone Cesaro; Cristiana Gasbarrino; Corrado Girmenia; Werner J Heinz; Raoul Herbrecht; Cornelia Lass-Flörl; Annamaria Nosari; Leonardo Potenza; Zdenek Racil; Volker Rickerts; Donald C Sheppard; Arne Simon; Andrew J Ullmann; Caterina Giovanna Valentini; Jörg Janne Vehreschild; Anna Candoni; Maria J G T Vehreschild Journal: Haematologica Date: 2013-05-28 Impact factor: 9.941
Authors: Sabiha Yasmin; Laura Alcazar-Fuoli; Mario Gründlinger; Thomas Puempel; Timothy Cairns; Michael Blatzer; Jordi F Lopez; Joan O Grimalt; Elaine Bignell; Hubertus Haas Journal: Proc Natl Acad Sci U S A Date: 2011-11-21 Impact factor: 11.205
Authors: Markus Schrettl; Nicola Beckmann; John Varga; Thorsten Heinekamp; Ilse D Jacobsen; Christoph Jöchl; Tarek A Moussa; Shaohua Wang; Fabio Gsaller; Michael Blatzer; Ernst R Werner; William C Niermann; Axel A Brakhage; Hubertus Haas Journal: PLoS Pathog Date: 2010-09-30 Impact factor: 6.823
Authors: G Luo; B Spellberg; T Gebremariam; H Lee; Y Q Xiong; S W French; A Bayer; A S Ibrahim Journal: Eur J Clin Microbiol Infect Dis Date: 2013-12-01 Impact factor: 3.267